去勢抗性攝護腺癌病患接受去癌達治療之臨床結果
鄭人豪、王賢祥、楊晨洸、歐宴泉、陳卷書、李建儀
臺中榮民總醫院外科部泌尿外科
Clinical outcomes in castration resistant prostate cancer patients treating with cabazitaxel
Jen-Hao Cheng, Shian-Shiang Wang, Cheng-Kuang Yang, Yen-ChuanOu, Chuan-Shu Chen, Jian-Ri Li.
Divisions of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
 
Purpose: The aim of this study was to assess the clinical outcomes of Cabazitaxel in treating castration resistant prostate cancer patients in Taichung Veterans General Hospital.
Materials and Methods: From Aug 2011 to Dec 2014, thirty-two patients with castration resistant prostate cancer were treated with Cabazitaxel 20-25mg/m2, IV, every three to four weeks. Thirty patients ever received prior docetaxel treatments.  The PSA response, pain response, time to progression duration and adverse events were recorded.
Results: The median age of the thirty-two patients was 65.7 years (range 45-84) and the median PSA when started Cabazitaxel was 65.5 ng/ml (range 3.82-5239). The mean treatment courses of the patient were 5.9 (range 3-17). PSA declined in twenty-two patients (69%, 22/32) and eighteen of them (56%, 18/32) got more than 50% declination (PSA response). The median progression free survival was 6 months. The most common subjective adverse effects were leukopenia (84%). Ten (31%) patients had grade 3-4 neutropenia and 4 (12.5%) patients had more than grade 2 anemia. Liver function impairment was also found in three (9%) patients.
Conclusions: Cabazitaxel 20-25mg/m2, IV, every three to four weeks were tolerated and revealed good PSA response in castration resistant prostate cancer patients. However, high risk of neutropenia should be kept in mind.
    位置
    資料夾名稱
    摘要
    發表人
    TUA秘書處
    單位
    台灣泌尿科醫學會
    標籤
    討論式海報
    建立
    2015-05-22 16:15:00
    最近修訂
    2015-05-22 16:15:59
    瀏覽
    1,410
    more